In vitro cultured allogeneic cytotoxic t cells mediate hematopoietic GVHD without gut GVHD despite expression of functional LPAM (α4β7 integrin)  by Kalpatthi, R. et al.
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RISK FACTORS ASSOCIATED WITH INCREASED GRADES III-IV ACUTE
GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (HCT)
Sorror, M.1, Gooley, T.1, Nash, R.1,2, Petersdorf, E.1,2, Martin, P.1,2,
Deeg, H.J.1,2, Baron, F.1, Davis, C.1, Sanders, J.1,2,
Flowers, M.E.D.1,2, Carpenter, P.1,2, Witherspoon, R.1,2,
Appelbaum, F.1,2, Storb, R.1,2 1. Fred Hutchinson Cancer Research
Center, Seattle, WA; 2. University of Washington, Seattle, WA.
Grades III-IV acute GVHD are associated with worse survival
compared to grades 0-II GVHD (Leukemia. 2004;18:1013). We in-
vestigated risk factors for development of grades III-IV GVHD
among 958 patients (pts) who received a myeloablative HCT between
1993 and 2002. Donor grafts were from HLA-identical siblings (n 
709) or unrelated donors who were matched for 10 of 10 HLA alleles
by high-resolution typing (n 249). GVHD prophylaxis consisted of
methotrexate (MTX) and cyclosporine (CSP). Conditioning included
120 mg/kg cyclophosphamide, combined with busulfan 16 mg/kg
(n  436) or 8-15 Gy fractionated total body irradiation (n  410).
Underlying diagnoses were classiﬁed as low-risk (acute leukemia-ﬁrst
remission, chronic myeloid leukemia-chronic phase, myelodysplasia-
refractory anemia, and non-malignant hematological disease) or high-
risk (other diagnoses). Pretransplant comorbidities were scored using
HCT-comorbidity index (HCT-CI, Blood. 2005;106:2912); where
35% of pts had scores 2-4, and 5% scores 5. After HCT, 15% of
related and 27% of unrelated pts developed grades III-IV acute
GVHD, respectively. Incidences of grades III-IV GVHD were 16%,
23%, and 45% for pts with HCT-CI scores of 0-3 vs 4 vs 5, and
15% vs 22% for pts with low vs high-risk diseases. Multivariable Cox
regression models were used to analyze possible risk factors for grades
III-IV GVHD. HCT-CI scores of5 (P .0001), high-risk diseases
(P .008), and80% CSP dosing (P.008) were associated with an
increased hazard of grades III-IV GVHD (Table 1). The magnitude
of these effects was similar between related and unrelated pts. MTX
dose 80% was a risk factor only among related pts (P  .02), and
unrelated grafts were a signiﬁcant risk factor among pts given 	80%
MTX dosing (P  .0001). Only 19 unrelated and 66 related pts
received 80% MTX dosing. The odds of receiving reduced dose of
CSP among pts 	20 years was 5.04 (95% CI, 2.99-8.5, P  .0001)
times that among pts 20 (incidences of reductions in CSP dosing
were 34%, 69%, 73%, and 76% among pts aged 20, 20-40, 40-50,
and 	50 years), although age was not statistically signiﬁcantly asso-
ciated with severe GVHD. The majority of pts 20 years had
HCT-CI scores of 0 (68%) vs 46% of older pts (P  .0002). These
results suggest that pts with high comorbidity scores or advanced
disease should be stratiﬁed in future clinical trials for GVHD pro-
phylaxis. The age related reductions of CSP dosing were likely due to
increasing comorbidities with increasing age (Table 1).
Table 1. Grades III–IV Acute GVHD
Risk Factors
Hazard
Ratio 95% CI
P
Value
HCT-CI scores 0–4 1 — —
>5 3.05 1.34–5.05 <.0001
Disease risk Low 1 — —
High 1.55 1.12–2.14 .008
CSP use* >120% 0.76 0.49–1.18 .23
80–120% 1 — —
<80% 1.95 1.19–3.18 .008
MTX use* (among
related recipients)
>80% 1 — —
<80% 1.96 1.12–3.57 .02
Donor (among pts
given >80% MTX
dosing)
Related
recipients
1 — —
Unrelated
recipients
2.60 1.68–3.31 <.0001
*Modeled as a time-dependent covariate, denotes percentage of
prescribed amount that was received. For CSP, % received is based
on prescribed amounts per week through 7 weeks post-transplant,
and for MTX, % received is based on amounts per day on days 1,
3, 6, and 11 (N Engl J Med 1986;314:729). Type of donor and %
MTX dosing show a statistically signiﬁcant interaction (P  .03).
Factors included in the analysis are: Patient age, donor age, type of
donor, TBI versus chemotherapy-based conditioning, doses of
TBI, disease risk, year of HCT, marrow vs peripheral blood mono-
nuclear cells, source of stem cells, and 80% reduction of doses of
CSP or methotrexate.
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ISOLATION AND CHARACTERIZATION OF HUMAN CD4CD25 T REG-
ULATORY CELLS FOR EARLY PHASE CLINICAL TRIALS IN HEMATOPOI-
ETIC CELL TRANSPLANTATION
Hou, J.-Z.1,2, Baker, J.1, Sheehan, K.1, Negrin, R.S.1 1. Division of
Bone Marrow Transplantation, Department of Medicine, Stanford Uni-
versity School of Medicine, Palo Alto, CA; 2. Division of Hematology,
Department of Medicine, Stanford University School of Medicine, Palo
Alto, CA.
Naturally occurring CD4CD25 T regulatory cells (Tregs)
are a subpopulation of CD4 T cells vital to homeostasis and
maintenance of tolerance. Tregs suppress the proliferation and
expansion of conventional CD25CD4 and CD8 T cells
through direct cell-cell contact. Our laboratory has shown that
co-transplantation of Tregs with conventional CD4 and CD8
T cells suppressed acute graft versus host diseases (GVHD) with-
out abrogating graft versus tumor (GVT) effects in murine bone
marrow transplant models. Translating this novel strategy holds
great promise not only in clinical hematopoietic cell transplanta-
tion, but also in adoptive cellular therapy beyond hematopoietic
cell transplantation. Large scale isolation of sufﬁcient human
Tregs for therapeutic application remains challenging. Tregs com-
prise 2-10% of CD4 T cells. In contrast to rodent Tregs, human
CD25 is also expressed at lower level by activated conventional T
cells or B cells. Here, we explore the isolation and characterization
of human CD4CD25 Tregs from peripheral blood mononu-
clear cells (PBMC) of healthy blood donors and from CD34 cell
depleted fraction of allogenic donors. CD25 cells were isolated
by three different approaches: 1) CD4 enrichment followed by
CD25 selection, 2) CD19 depletion followed by CD25 selec-
tion, 3) CD25 selection without prior enrichment or depletion.
The purities of isolated CD4CD25 cells were 95%, 93%, and
93% respectively. The isolated CD25 cells were then sorted
into CD4CD25High and CD4CD25Low, ﬁxed and stained
for intracellular expression of FoxP3. More than 95% of
CD4CD25bright cells expressed FoxP3. In contrast, only 30-
40% of CD4CD25dim cells expressed FoxP3. No FoxP3 ex-
pression was detected in CD4CD25 cells. Using multi-color
FACS, we observed that human FoxP3CD4CD25High cells
express high levels of CD27 (98%), CD28 (100%), and CD30
(50%) and low levels (10%) of CTLA-4, GITR, 4-1BB, PD-1
and ICOS on the cell surface. However, CTLA-4, GITR, PD-1
and ICOS were expressed intracellularly in more than 50% of
FoxP3CD4CD25High cells. OX40, TRAIL, ICOS ligand
and FasL were not detected on the cell surface or in the cyto-
plasm of FoxP3CD4CD25bright cells. In summary, highly
puriﬁed CD4CD25 Treg cells can be isolated by magnetic
beads and cell sorting. Importantly, the majority of the cells
express FoxP3. Utilizing this technique, the clinical application
of Tregs appears feasible.
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IN VITRO CULTURED ALLOGENEIC CYTOTOXIC T CELLS MEDIATE
HEMATOPOIETIC GVHD WITHOUT GUT GVHD DESPITE EXPRESSION
OF FUNCTIONAL LPAM (	47 INTEGRIN)
Kalpatthi, R., Nicol, K., Hendey, L., Boyer, M. Children’s Hospital,
Columbus, OH.
We and others have shown that in vitro cultured CD8 cyto-
toxic T cells (CTL) have attenuated GVHD. It has been shown
that expression of LPAM on CD8 T cells is important for gut
homing speciﬁcity in GVHD. Recently, retinoic acid (RA) has
been shown to upregulate LPAM expression on naive T cells.
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We hypothesize that in vitro cultured CTL without RA lack the
ability to cause GVHD in part due to deﬁcient LPAM expres-
sion. We used an established murine GVHD model in which
B6SJL Sp/LN cells were stimulated against DBA splenocytes
with IL-2 and IL-7 with and without addition of RA (100 nm).
Day 14 comparison of CTL and CTLRA revealed comparable
CD4 and CD8 populations. CTL with and without RA showed
CD8 LPAM expression of 58% and 0.8% and CD8 CCR9 53%
and 10% respectively. In vitro cytotoxicity was comparable be-
tween CTL and CTLRA: 41% vs 51% (n  3, P  .30). Both
CTL groups had comparable in vitro migration towards SDF
(P  ns) but CTLRA had increased migration towards TECK;
17.3% vs 4.6% (n  4, P  .01). For in vivo homing, 107 labeled
cells from each CTL with (CFSE) and without RA (TRITC)
were coinjected intravenously and analysed after 16 hours.
CTLRA had increased homing to Peyers patch and MLN com-
pared to CTL without RA [homing index (CTLRA/CTL) 2.3
and 2.5 respectively]. This ﬁnding is exaggerated in the radiated
host [homing index (CTLRA/CTL) 15 for PP and 11 for
MLN]. CTL and CTLRA (5  106 cells each) were injected
intravenously with or without C57BL/6J BM into irradiated
(600 rads) B6D2F1 recipients (6 groups; radiation control,
CTL, CTLRA, BM control, CTL  BM, CTLRA  BM). Mice
were followed for clinical GVHD scores and CBC and his-
topathologic GVHD scores (liver, skin, lung, small and large
intestines) were obtained. Both CTL groups without BM rescue
developed lethal BM aplasia around day 24; however, his-
topathologic GVHD scores were similar (Table 1). CTL and
CTLRA groups with BM rescue had full hematopoietic recov-
ery, yet had similar histopathologic GVHD scores (BM control;
3.9, CTL  BM; 5, CTLRA  BM: 3.9, P  ns). Our data
demonstrate that both CTL and CTLRA cause a lethal hema-
topoietic GVH reaction which could be abrogated by parent
BM. Despite high LPAM and CCR9 expression, signiﬁcant in
vitro migration to TECK and in vivo homing to gut associated
lymphoid tissues, RA treated CTL did not cause signiﬁcant
GVHD in gut, liver or skin. This suggests that defective gut
homing alone may not be sufﬁcient to explain the attenuated
GVHD from cultured CTL (Table 1).
Table 1. Data from Day 24 Sacriﬁce
Parameter (Mean)
Radiation
Control CTL CTLRA
P
Value*
Hb (g/dL) 12.2 3.8 3.1 .0001
WBC  106/L 1000 300 300 .07
Platelets  103/L 667 200 50 200 29 500 .003
Combined GVHD
histology score
4.9 4.4 4.2 .30
*CTL or CTLRA vs radiation control group.
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EARLY TREATMENT WITH CD4CD25 REGULATORY T CELLS PRO-
VIDES PROLONGED SUPPRESSIVE EFFECTS WHICH CONTROL EVOLV-
ING BUT NOT ESTABLISHED GRAFT-VERSUS-HOST-DISEASE
Nguyen, V.H., Zeiser, R., Dasilva, D., Negrin, R.S. Stanford Univer-
sity School of Medicine, Stanford, CA.
In our previous study with Treg trafﬁcking, bioluminescence imag-
ing (BLI) indicated a persistence of signal consistent with a prolonged
survival of Treg in vivo following allogeneic bone marrow transplan-
tation. In the current study, we evaluated the duration of Treg sup-
pression and the impact of Treg on evolving and established GvHD.
Lethally irradiated Balb/c (H2d) hosts received 5  106 T-cell de-
pleted bone marrow cells from wild-type FVB mice (H2q) on day 0.
On day 2, 3 106 splenocytes, or 1 106 puriﬁed CD4/CD8 T
cells (Tcon) from luciferase transgenic mice (FVB) were infused to
induce GvHD. Treg, puriﬁed from wt-FVB mice, in a 1:1 dose ratio
with Tcon, were infused either on day 0, 2, 9, or 23 post-transplan-
tation. BLI was used to localize and quantify the proliferation of Tcon
in the absence or presence of Treg. Signal intensity, measured by
photons/second/mouse, was signiﬁcantly decreased in animals which
received Treg at day 0, 2, or 9 (P  .05). Importantly, the greatest
reduction in signal intensity occurred when Treg were given prior to
the induction of GvHD by Tcon. This reduction was associated with
a signiﬁcantly lower clinical score for GvHD. Studies in which Treg
are given up to 10 days prior to the addition of Tcon show similar
ﬁndings. At day 23, when clinical GvHD was fully established in mice
which received Tcon, the addition of Treg did not alter the increasing
BLI signal level or the clinical course such that all animals died of
GvHD (P  .38). Lymphoid reconstitution was not affected by the
addition of Treg prior to the induction of GvHD. In dose titration
studies whereby Treg are given two days prior to the induction of
GvHD, a 10-fold dose reduction in Treg was sufﬁcient to signiﬁcantly
reduce Tcon proliferation and suppress clinical GvHD. We next
assessed the duration of Treg suppressive effect by inducing GvHD
on day 7, 14, 19 with lucTcon following the infusion ofTreg on day
0 of allogeneic BMT. Treg provided protection from the Tcon
challenge at all 3 time points, leading to improved survival (P  .05).
We conclude that Treg provide prolonged protection due to their
ability to proliferate in vivo in an allogeneic setting, permitting a
signiﬁcant reduction in the number of Treg needed for adoptive
transfer to induce a clinical response. In addition, we conclude that
Treg suppress the early proliferation of Tcon, allowing them to
prevent and control evolving but not established GvHD.
157
INTERLEUKIN-2 (IL-2) AND GRANULOCYTE-MACROPHAGE STIMULAT-
ING FACTOR (GM-CSF) FOR TREATMENT OF RELAPSE AFTER ALLOGE-
NEIC STEM CELL TRANSPLANT (ASCT)
Bachier, C.R., Shaughnessy, P., Wall, D., Grimley, M., LeMaistre, C.F.
Texas Transplant Institute, San Antonio, TX.
Donor lymphocyte infusion (DLI) is commonly used for relapse
after allogeneic stem cell transplant (ASCT). Immune activation
with cytokines is an alternative to DLI. We report a retrospective
analysis and ﬁrst 6 patients (pts) of a prospective study evaluating
the safety and efﬁcacy of granulocyte-macrophage stimulating fac-
tor (GM-CSF) and interleukin-2 (IL-2) administered at the time of
relapse after ASCT in pts with hematologic malignancies. Pts
received subcutaneous GM-CSF at 250 g/day on days 1-14 and
IL-2 at 1  106 units/m2/day on days 8-14. Pts were off of
immunosuppressive therapy and had no prior history of graft
versus host disease (GVHD) at the start of treatment. A total of 10
pts have received cytokine therapy with IL-2/GM-CSF for treat-
ment of relapsed AML (6), ALL (2), CML (1), MDS (1). Median
age was 45 (range 8-61). Stem cell source included: peripheral
blood  7, bone marrow  2, umbilical cord blood (UCB)  1.
Donor sources were matched-related sibling  3, matched-unre-
lated donor  7 (UCB  1). Seven pts had resistant relapse or
primary resistant disease at time of ASCT. Median time from
transplant to relapse was 4 months (range  1-14 months). Two
pts had failed DLI and 5 pts had received reinduction chemother-
apy prior to IL-2/GM-CSF. Seven pts responded to IL-2/GM-
CSF (CR  6, PR  1). Two pts remain disease free at 18 and 26
months post IL-2/GM-CSF. Six pts developed GVHD (4/6 re-
sponders). Two pts had GM-CSF discontinued due to increase in
peripheral blood blasts. No other toxicities were related to IL-2/
GM-CSF except for ﬂu-like symptoms and bone pains. In conclu-
sion, cytokine therapy with IL-2/GM-CSF is feasible and we
continue accrual to determine if this cytokine regimen is an alter-
native to DLI for relapse after ASCT.
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ELEVATED B CELL ACTIVATING FACTOR (BAFF) IN PATIENT PLASMA
AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IS A POTENTIAL
BIOMARKER FOR CHRONIC GRAFT VERSUS HOST DISEASE
Sarantopoulos, S., Zorn, E., Bhuiya, N.S., Kim, H.T., Soiffer, R.J.,
Cutler, C.S., Levin, J., Antin, J.H., Ritz, J. Division of Hematologic
Malignancies, Dana Farber Cancer Institute, Boston, MA.
Previous studies have identiﬁed a highly signiﬁcant correlation
between speciﬁc antibody responses directed against recipient
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